LQDA | Ticker Profile - Titan Protect

LQDA

Liquidia Corporation

Healthcare · Drug Manufacturers - Specialty & Generic · NCM

$61.85

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$5.5B

Total market value of the company

Trailing P/E

364.85

Expensive — high growth expected

Forward P/E

11.13

Based on estimated future earnings — lower means cheaper

Rev Growth

+4,158.5%

Year-over-year revenue change

Profit Margin

7.7%

How much profit the company keeps from each dollar of revenue

ROE

28.2%

Return on equity — how efficiently it uses shareholder money

Analyst Target

N/A

Recommendation

NONE

Consensus view from 8 analysts covering this stock

About Liquidia Corporation

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.

https://www.liquidia.com

Country: United States Employees: 216 Industry: Drug Manufacturers - Specialty & Generic

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

1.570

Excellent risk-adjusted returns

Kelly Fraction

0.1307

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

3.225

Returns exceed worst-case losses — strong risk profile

Annual Return

124.6%

Historical annualised return based on price data

Max Drawdown

-38.6%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.42

Very low correlation to market moves

52W High

$63.46

3% below the year high

52W Low

$11.85

422% above the year low

Avg Volume

1,379,495

Average daily shares traded — higher means easier to buy and sell

Short Ratio

6.6

Days it would take all short sellers to cover — higher means more crowded

Short % Float

14.3%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$0.17

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

170.22

Heavy leverage — higher financial risk if revenues decline

Current Ratio

2.22

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

1.98

Like current ratio but excludes inventory — stricter test

Gross Margin

91.8%

Revenue left after cost of goods — higher means pricing power

Operating Margin

46.3%

Profit from core operations before interest and tax

Free Cash Flow

$10M

Positive — the business generates more cash than it spends

Revenue (TTM)

$288M

Total revenue over the last 12 months

Net Income

$22M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$70.00

Target Median

$N/A

Target Low

$59.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go